PDCD1 and urothelial carcinoma: Patients who responded to treatment with anti-PD-1/L1 antibodies in a study of patients with metastatic or locally advanced urothelial carcinoma were almost twice as likely to report associated adverse events or associated immune-mediated adverse events [23].